<DOC>
	<DOCNO>NCT02433587</DOCNO>
	<brief_summary>The primary objective trial evaluate short versus long duration dual antiplatelet therapy patient undergo low extremity endovascular revascularization .</brief_summary>
	<brief_title>Evaluation Short Versus Long Duration Dual Antiplatelet Therapy Patients Undergoing Lower Extremity Endovascular Revascularization</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>1 . Provide sign informed consent initiation study relate procedure 2 . Be least 18 year age 3 . Successful percutaneous low extremity ( iliac infrainguinal ) endovascular revascularization ( percutaneous transluminal angioplasty , /or stent ) . 4 . At least 1 vessel runoff segment distal intervention 5 . Rutherford Classification 25 unresponsive medical therapy 1 . Acute limb ischemia 2 . Procedure include device deployment specific FDA regulation anticoagulation/antiplatelet medication regimen . 3 . Patient undergo atherectomy procedure 4 . Intervention include deployment drug elute stent 5 . Critical limb ischemia ( Rutherford Classification 6 ) 6 . Thrombocytopenia : Platelet count &lt; 50k 7 . Liver disease ( ChildsPugh B C ) 8 . Existing need go clopidogrel therapy 9 . Proton Pump Inhibitor Use ( If unable switch ) 10 . Need therapeutic anticoagulation 11 . Known hypercoagulable disorder 12 . Allergy contraindication aspirin clopidogrel 13 . Pregnancy 14 . Patients enrol another investigational drug device study within past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>